Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Biogen announced it will present Phase 2 CELIA data for its investigational tau-targeting therapy diranersen (BIIB080) and new analyses for LEQEMBI at the Alzheimer’s Association International Conference (AAIC) 2026. The diranersen presentation will cover clinical, biomarker, and safety results from an 18-month study involving 416 patients with early Alzheimer’s disease, building on topline results released in May 2026.
Key figures
- Drug Name
- Diranersen (BIIB080)
- Phase Of Trial
- Phase 2
- Pdufa date
- 2026-08-24
- Celia participants
- 416
- Primary endpoint week
- 76
- Study duration months
- 18
- Leqembi approval countries
- 53
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.